Ad
related to: shockwave medical merger- M&A Market News
Explore our latest coverage on the
mergers and acquisition space.
- Deals Data
See detailed data on deals
in the private and public markets.
- M&A Deal Data
Get insight into valuable and up to
date M&A deals in any industry.
- Morningstar Research
Morningstar is a leading provider
of independent investment research.
- M&A Market News
Search results
Results From The WOW.Com Content Network
(Reuters) -Johnson & Johnson is in talks to buy medical device maker Shockwave Medical, the Wall Street Journal reported on Tuesday, as the healthcare giant potentially looks to expand its ...
(Reuters) -Johnson & Johnson on Friday agreed to buy Shockwave Medical in a deal valued at $13.1 billion including debt, as it builds its cardiac-health-centric medical devices business to help ...
Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries. The health care ...
Johnson & Johnson announced several acquisitions in 2024: Ambrx Biopharma for $2 billion (in January), [88] Shockwave Medical for $13.1 billion (in April), [89] [90] [91] and Proteologix for $850 million (in May). [92] Johnson & Johnson announced it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion. [93]
Shockwave Medical: S&P 500 constituent Johnson & Johnson acquired Shockwave Medical. ... Healthcare Trust of America acquired Healthcare Realty Trust. Post-merger ...
LivaNova, plc is an Italian-American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation.The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. [2] The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
For premium support please call: 800-290-4726 more ways to reach us
The World Health Organization called noninvasive hemoglobin an "innovative medical technology for cost-effectively addressing global health concerns and needs". [ 34 ] In October 2014, Masimo announced CE Marking of Oxygen Reserve Index or ORi, the company's 11th noninvasive parameter, which provides real-time visibility to oxygenation status.